Methods and compositions for the treatment of alzheimer's disease
D-beta-hydroxybutyrate compositions, administered intranasally, address the limitations of current Alzheimer's therapies by reducing disease symptoms and progression through elevated brain levels, improving behavioral and physical outcomes in animal models.
Patent Information
- Application Number
- PCT/US2025/052030
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-23
- Filing Date
- 2025-10-22
- Publication Date
- 2026-04-30
AI Technical Summary
Current therapies for Alzheimer's disease are limited, and there is a need for new methods and compositions to treat, prevent, and ameliorate the disease, which is characterized by progressive memory loss and neurodegenerative symptoms such as amyloid plaques and neurofibrillary tangles.
Administering a therapeutically effective amount of D-beta-hydroxybutyrate, optionally with a pharmaceutically acceptable carrier, potentially combined with anti-amyloid plaque agents, cholinesterase inhibitors, glutamate regulators, or orexin receptor antagonists, via intranasal administration to elevate brain D-beta hydroxybutyrate levels, thereby reducing symptoms of Alzheimer's disease.
The administration of D-beta-hydroxybutyrate compositions effectively ameliorates symptoms of Alzheimer's disease, including amyloid plaques and neurofibrillary tangles, by improving behavioral and physical symptoms in animal models, such as increased body weight, improved nesting behavior, and enhanced sensorimotor gating, while potentially delaying disease progression.